GlaxoSmithKline Egypt S.A.E. specializes in the development, manufacture and marketing of medicines. Their products are for the treatment of diabetes, asthma, cancer, hepatic viruses, infections, allergies and gastro-intestinal and cardiovascular diseases.

Employees

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
01/07/26	EGP 71.48	+3.26%	28,729
30/06/26	EGP 69.22	+1.54%	14,042
29/06/26	EGP 68.17	+1.17%	31,113
28/06/26	EGP 67.38	-5.68%	62,209
25/06/26	EGP 71.44	+0.59%	40,539

End-of-day quote Egyptian Exchange

More quotes

Income Statement and Estimates

More financial data

End-of-day quote Egyptian Exchange Other stock markets 01/07/2026			5-day change	1st Jan Change
71.48 ^EGP	+3.26%		+0.06%	+12.30%

05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
03-12	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI

Market Cap	5.97B 122M 106M 97.63M 91M 173M 11.57B 175M 1.17B 456M 5.69B 456M 446M 19.6B	P/E 2024	17.3x	P/E 2025	24.9x
Enterprise Value	5.57B 113M 99.15M 91.12M 84.93M 161M 10.8B 164M 1.09B 425M 5.31B 426M 417M 18.29B	EV / Sales 2024	1.02x	EV / Sales 2025	1.32x
Free-Float	2.91%	Yield 2024 *	-	Yield 2025	1.57%

05-17	GlaxoSmithKline Q1 consol net profit EGP 4.7 million	RE
03-12	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-12	GlaxoSmithKline FY dividend EGP 0.75 per share	RE
03-12	GlaxoSmithKline FY consol profit EGP 213.2 million	RE
12-30	GlaxoSmithKline S.A.E announces Annual dividend, payable on January 14, 2026	CI
11-19	GlaxoSmithKline S.A.E Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
11-13	GlaxoSmithKline Q3 consol loss EGP 34.8 million	RE
12/08/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
12/08/25	GlaxoSmithKline posts Q2 consol profit EGP 5.9 mln	RE
14/05/25	GlaxoSmithKline S.A.E Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
14/05/25	Glaxosmithkline Reports Q1 Net Profit EGP 43.5 Million	RE
09/03/25	GlaxoSmithKline S.A.E Reports Earnings Results for the Full Year Ended December 31, 2024	CI
09/03/25	Glaxosmithkline FY Dividend EGP 1 Per Share	RE

10/03/22	GlaxoSmithKline E : Glaxo Smith Kline (BIOC.CA) - Listing Committee Decision	PU
20/12/21	GSK hires former Tesco boss Sir Dave Lewis to head up £40bn spin-off	AQ

GlaxoSmithKline S.A.E Stock

Stocks

BIOC

EGS38171C012

Pharmaceuticals

Valuation: GlaxoSmithKline S.A.E

Chart: GlaxoSmithKline S.A.E

Latest news : GlaxoSmithKline S.A.E

Press Releases: GlaxoSmithKline S.A.E

Quotes and Performance

Course Extremes

Managers and Directors: GlaxoSmithKline S.A.E

Other Pharmaceuticals

Financials

Company Profile

Quotes

Income Statement and Estimates

1 day	+3.26%
1 week	+0.06%
Current month	+3.26%
1 month	-1.76%
3 months	+16.68%
6 months	+12.30%
Current year	+12.30%

1 week	66.75	72.8
1 month	66.75	75.5
Current year	55.1	79.99
1 year	38.06	81.5
3 years	24.7	81.5
5 years	16.66	81.5
10 years	0	81.5

Director	Title	Age	Since
Sherine El-Ansari BRD	Director/Board Member	-	-
Ashraf Mohammed Ibrahim Mansour CHM	Chairman	-	-
Munir Ghabour Hanna BRD	Director/Board Member	-	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GLAXOSMITHKLINE S.A.E	+3.26%	+0.06%	+86.83%	+123.79%	122M
ELI LILLY AND COMPANY	+1.86%	+0.48%	+55.50%	+163.08%	1,082B
JOHNSON & JOHNSON	+3.57%	+3.29%	+68.60%	+61.03%	633B
ABBVIE INC.	+3.99%	+3.05%	+37.93%	+93.37%	461B
ROCHE HOLDING AG	+3.86%	+1.64%	+32.57%	+24.89%	338B
ASTRAZENECA PLC	-0.56%	+0.96%	+41.67%	+39.35%	299B
NOVARTIS AG	-0.08%	+1.30%	+32.15%	+44.48%	291B
NOVO NORDISK A/S	-1.54%	+2.81%	-25.35%	-39.61%	222B
AMGEN INC.	+3.55%	+4.41%	+25.45%	+66.28%	202B
GILEAD SCIENCES, INC.	+4.21%	+2.65%	+17.47%	+71.11%	163B
Average	+2.21%	+4.13%	+37.28%	+64.78%	369.25B
Weighted average by Cap.	+2.25%	+5.53%	+42.31%	+83.31%

	2024	2025
Net sales	2.99B 60.88M 53.22M 48.91M 45.59M 86.47M 5.8B 87.78M 587M 228M 2.85B 229M 224M 9.82B	3.73B 75.94M 66.39M 61.01M 56.87M 108M 7.23B 109M 732M 285M 3.55B 285M 279M 12.25B
Net income	174M 3.54M 3.1M 2.85M 2.65M 5.03M 337M 5.11M 34.16M 13.28M 166M 13.29M 13.01M 571M	213M 4.34M 3.79M 3.49M 3.25M 6.16M 413M 6.26M 41.86M 16.27M 203M 16.29M 15.94M 700M
Net Debt	44.01M 896K 783K 720K 671K 1.27M 85.3M 1.29M 8.64M 3.36M 41.93M 3.36M 3.29M 144M	-398M -8.1M -7.08M -6.51M -6.07M -11.51M -771M -11.68M -78.13M -30.37M -379M -30.41M -29.75M -1.31B